Marc de Garidel, CinCor Pharma CEO (Eric Piermont/AFP via Getty Images)
CinCor’s hypertension candidate flops a PhII test but plans to charge ahead with pivotal study
Toward the end of summer, Massachusetts-based CinCor Pharma was riding high with a $225 million raise, touting a positive data readout. But a closer look …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
